查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836814

兒科疫苗市場（按疫苗類型、疾病、技術、最終用戶和年齡分類）—2025-2032 年全球預測

Pediatric Vaccines Market by Vaccine Type, Disease, Technology, End User, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，兒科疫苗市場將成長 523 億美元，複合年成長率為 11.90%。

主要市場統計數據
基準年2024年 212.6億美元
預計2025年 238.3億美元
預測年份：2032年 523億美元
複合年成長率（%） 11.90%

重點介紹創新、政策、供應彈性和相關人員期望的交叉力量，這些力量決定了當代兒科疫苗策略

兒童疫苗接種仍然是我們這個時代最重要的公共衛生干預措施之一，其基礎是臨床科學、公共、採購架構和生產能力的複雜相互作用。過去十年，抗原設計、偶聯技術和製劑組合方面的進步擴展了嬰兒、兒童和青少年的預防套件包，使人們能夠以更少的注射次數和更便捷的接種時間獲得更廣泛的保護。同時，流行病學的演變、家長期望的提高以及支付方優先事項的變化，迫使疫苗相關人員重新評估供應彈性和價值提案。

因此，製造、分銷和公共衛生組織的領導者必須協調快速的技術進步與持續的營運現實。低溫運輸的完整性、跨轄區監管的一致性以及組合藥物的經濟性都會影響專案實施的可行性。因此，對這一領域的實際介紹必須突出技術創新如何轉化為可部署的解決方案，同時認知到影響採用和獲取的系統性限制因素。本摘要為深入探討變革性轉變、細分市場細微差別、區域差異以及建議的行動奠定了基礎，旨在為近期的決策者指南。

影響兒科疫苗開發、生產和引進動態的主要技術、監管和供應模式轉移的分析概述

兒科疫苗領域正在經歷一場變革性轉變，這得益於技術突破、政策重點轉變以及新的給藥模式，這些模式正在重新定義疫苗的設計、生產和給藥方式。重組和結合技術的進步使得疫苗的抗原覆蓋範圍更廣，免疫抗原性，而聯合疫苗則減少了就診次數，並簡化了免疫接種程序。同時，製造商正在採用模組化和靈活的生產方式，以快速響應需求波動並支援本地化的供應鏈。

在政策方面，各方明顯推動監管協調和加速核准框架，以縮短針對高負擔兒童疾病的疫苗上市時間。籌資策略也不斷發展，採購方強調整體擁有成本、供應保證條款以及培訓和低溫運輸援助等生命週期服務。數位化健康和免疫登記系統開始支援更有針對性的推廣和覆蓋率監測，從而提高了衡量實際影響和根據持續存在的差異量身定做宣傳活動的能力。公眾信任和傳播策略仍然至關重要，衛生當局和製造商應投資於透明的安全溝通和社區參與，以在不同人群中保持較高的疫苗接種率。

清楚評估近期關稅措施如何影響供應鏈決策、籌資策略和兒科疫苗生產地理

2025年宣布的貿易政策變化，包括影響藥品和生技藥品投入的新關稅措施，正在對兒科疫苗價值鏈產生累積影響，加劇成本壓力，鼓勵供應商多元化，並加速近岸外包談判。特種佐劑、無菌灌裝耗材和一次性生物反應器零件等原料已成為採購團隊探索替代籌資策略以減輕關稅影響的重點。因此，製造商和採購負責人重新審視了合約條款和庫存策略，以確保免疫接種項目能夠持續進行。

為應對這項挑戰，一些製造商正在將投資轉移到區域製造地，以降低跨境關稅風險並縮短前置作業時間。由於建立能夠生產生技藥品的設施需要熟練的人員並遵守嚴格的品質框架，此類策略性遷移會影響東道國的監管趨同和勞動力發展。對採購者而言，關稅環境凸顯了透明的土地成本分析以及與供應商合作共擔風險安排的重要性。最終，這些影響促使採購團隊和政策制定者需要進行基於情境的規劃，評估貿易政策的突發事件以及公共衛生優先事項，以維持弱勢兒科族群的免疫接種機會。

全面的細分洞察，將產品類型、疾病目標、技術、最終用戶管道和人口統計數據與策略臨床和商業性影響聯繫起來

細分分析揭示了產品、疾病、技術、最終用戶和年齡層等類別如何推動兒科免疫計劃的差異化開發和交付考慮。依疫苗類型，市場分為四類：六價、單價、五價和四價。六價製劑等聯合疫苗強調程序上的便利性和時間壓縮，而單價製劑在疫情應對和加強策略方面仍具有戰略意義。依疾病，研究涵蓋 DTP、B型肝炎、Hib、麻疹、肺炎鏈球菌、脊髓灰質炎和輪狀病毒。對於 DTP，進一步的分析涵蓋白喉、百日咳和破傷風。疾病特異性動態，例如肺炎鏈球菌感染的血清型多樣性和輪狀病毒的基因型多樣性，影響抗原選擇和監測重點。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大mRNA技術在兒科疫苗研發的應用，對抗新興病原體
  • 增加聯合疫苗的使用，以減輕兒童的注射負擔
  • 傳播數位追蹤工具，提高兒童疫苗接種依從性和覆蓋率
  • 更重視疫苗公平舉措，以擴大服務不足的兒科族群的疫苗接種機會
  • 開發無針給藥方法以提高嬰幼兒疫苗接種率

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 兒科疫苗市場（依疫苗類型）

  • 六價
  • 單身的
  • 五價
  • 四價

9. 兒科疫苗市場（依疾病）

  • DTP
    • 白喉
    • 百日咳
    • 破傷風
  • B型肝炎
  • 乙型流感嗜血桿菌
  • 麻疹
  • 肺炎球菌
  • 脊髓灰質炎
  • 輪狀病毒

10.兒科疫苗市場（依技術）

  • 複雜類型
    • 多醣複合物
    • 蛋白質複合物
  • 惰性
    • 類毒素
    • 病毒性的
  • 減毒變態
    • 細菌
    • 病毒性的
  • 重組
    • 哺乳動物細胞培養
    • 酵母基
  • 次單元
    • 胜肽次單元
    • 蛋白質次單元

第 11 章兒科疫苗市場（依最終用戶）

  • 診所
    • 綜合診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 疫苗接種中心
  • 藥局
    • 醫院藥房
    • 零售藥局

12. 兒童疫苗市場（依年齡層）

  • 青年
  • 孩子
  • 嬰兒
  • 新生
  • 嬰兒

13. 兒科疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章兒科疫苗市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國兒科疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Sanofi SA
    • Serum Institute of India Private Limited
    • Bharat Biotech International Limited
    • PT Bio Farma（Persero）
    • Sinovac Biotech Ltd.
    • CSL Seqirus Pty Ltd.
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-030EE4851566

The Pediatric Vaccines Market is projected to grow by USD 52.30 billion at a CAGR of 11.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.26 billion
Estimated Year [2025] USD 23.83 billion
Forecast Year [2032] USD 52.30 billion
CAGR (%) 11.90%

A focused introduction outlining the intersecting forces of innovation, policy, supply resilience, and stakeholder expectations that define modern pediatric vaccine strategies

Pediatric vaccination remains one of the most consequential public health interventions of the modern era, underpinned by complex interactions among clinical science, public policy, procurement architecture, and manufacturing capability. Over the past decade, advances in antigen design, conjugation techniques, and combination formulations have expanded the preventive toolkit for infants, toddlers, children, and adolescents, raising expectations for broader protection with fewer injections and simpler schedules. At the same time, evolving epidemiology, heightened parental expectations, and shifting payer priorities have pushed vaccine stakeholders to re-evaluate supply resilience and value propositions.

Consequently, leaders across manufacturing, distribution, and public health institutions must reconcile rapid technological progress with persistent operational realities. Cold chain integrity, regulatory alignment across jurisdictions, and the economics of combination products all influence the feasibility of programmatic uptake. Therefore, a pragmatic introduction to this landscape needs to foreground how innovation translates into deployable solutions, while acknowledging the systemic constraints that shape adoption and access. This summary sets the stage for a deeper examination of the transformative shifts, segmentation nuances, regional differentials, and recommended actions that will guide decision-makers in the near term.

An analytical overview of the major technological, regulatory, and delivery paradigm shifts reshaping pediatric vaccine development manufacturing and uptake dynamics

The pediatric vaccine landscape is experiencing transformative shifts driven by technological breakthroughs, altered policy priorities, and new delivery paradigms that collectively redefine how protection is designed, produced, and delivered. Advances in recombinant and conjugate technologies have enabled broader antigen coverage and improved immunogenicity, allowing combination vaccines to reduce clinic visits and streamline immunization schedules. Concurrently, manufacturers are adopting modular and flexible production approaches to respond faster to demand fluctuations and to support regionally localized supply chains.

On the policy side, there is a visible push toward harmonized regulatory pathways and accelerated approval frameworks to shorten time-to-market for vaccines that address high-burden pediatric diseases. Procurement strategies are also evolving; purchasers are increasingly weighing total cost of ownership, supply assurance clauses, and lifecycle services such as training and cold chain support. Digital health and immunization registries are beginning to underpin more targeted outreach and coverage monitoring, enhancing the ability to measure real-world impact and to tailor campaigns to persistent gaps. Public trust and communication strategies remain critical, with health authorities and manufacturers investing in transparent safety communication and community engagement to maintain high uptake across diverse populations.

A clear-eyed assessment of how recent tariff measures have influenced supply chain decisions procurement strategies and the geographic distribution of pediatric vaccine production

Trade policy changes announced in 2025, including new tariff measures affecting pharmaceuticals and biologics inputs, have had a cumulative impact on pediatric vaccine value chains by amplifying cost pressures, encouraging supplier diversification, and accelerating nearshoring conversations. Raw materials such as specialized adjuvants, consumables for aseptic filling, and single-use bioreactor components became focal points for procurement teams seeking alternative sourcing strategies to mitigate tariff exposure. As a result, manufacturers and procurers have re-examined contractual terms and inventory strategies to sustain uninterrupted immunization programs.

In response, some producers have shifted investments toward regional manufacturing hubs to reduce cross-border tariff risk and to shorten lead times. This strategic relocation has implications for regulatory convergence and workforce development in host regions, because establishing biologics-capable facilities demands skilled personnel and compliance with stringent quality frameworks. For purchasers, the tariff environment has heightened the importance of transparent landed cost analyses and collaborative risk-sharing arrangements with suppliers. Ultimately, these effects have reinforced the need for scenario-based planning, where procurement teams and policy-makers evaluate trade policy contingencies alongside public health priorities to preserve immunization access for vulnerable pediatric populations.

Comprehensive segmentation insights connecting product types disease targets technologies end-user channels and age cohorts to strategic clinical and commercial implications

Segmentation analysis reveals how distinct product, disease, technology, end-user, and age-group categories drive differentiated development and delivery considerations across pediatric immunization programs. Based on Vaccine Type, market is studied across Hexavalent, Monovalent, Pentavalent, and Quadrivalent; combination vaccines such as hexavalent formulations emphasize programmatic convenience and schedule compression, while monovalent products retain strategic relevance for targeted outbreak responses and booster strategies. Based on Disease, market is studied across DTP, Hepatitis B, Hib, Measles, Pneumococcal, Polio, and Rotavirus. The DTP is further studied across Diphtheria, Pertussis, and Tetanus; disease-specific dynamics-such as serotype diversity in pneumococcal disease or genotypic variation in rotavirus-inform antigen selection and surveillance priorities.

Based on Technology, market is studied across Conjugate, Inactivated, Live Attenuated, Recombinant, and Subunit. The Conjugate is further studied across Polysaccharide Conjugate and Protein Conjugate. The Inactivated is further studied across Toxoid and Viral. The Live Attenuated is further studied across Bacterial and Viral. The Recombinant is further studied across Mammalian Cell Culture and Yeast Based. The Subunit is further studied across Peptide Subunit and Protein Subunit; these technological distinctions have direct implications for manufacturing complexity, cold chain requirements, and immunogenicity profiles, shaping both R&D prioritization and capital expenditure decisions. Based on End User, market is studied across Clinics, Hospitals, Immunization Centers, and Pharmacies. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies; distribution and training investments need to align with the dominant end-user channels in a given geography to ensure timely availability and correct administration practices. Based on Age Group, market is studied across Adolescents, Children, Infants, Neonates, and Toddlers, and tailoring formulation, dosing regimen, and delivery mechanisms to the physiological and programmatic needs of each age cohort remains a core determinant of clinical adoption and program success.

Interacting across these segmentation axes, certain patterns emerge: combination vaccines and conjugate technologies trend toward integrated programmatic value, whereas recombinant and subunit platforms offer flexible upgrade pathways for antigenic modification. End-user distribution preferences condition packaging and presentation choices, and age-group specific requirements drive formulation constraints and stability demands. Recognizing these layered segmentation realities enables stakeholders to prioritize product portfolios and operational investments that match clinical needs and delivery channel realities.

Regionally differentiated intelligence on regulatory harmonization manufacturing capacity and programmatic priorities across varied global geographies that shape vaccine access and supply

Regional dynamics exert a decisive influence on vaccine strategy, shaping manufacturing footprints, regulatory timelines, and programmatic deployment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory agility and established immunization infrastructure support rapid introduction of combination products, while public and private payers increasingly emphasize value-based procurement and supply assurance mechanisms. Supply chain nodes in North and Latin America also prioritize cold chain optimization and data-driven coverage monitoring to address urban-rural disparities.

Within Europe, Middle East & Africa, heterogeneity in regulatory frameworks and procurement capacity creates a dual imperative: harmonize standards to enable efficient market entry, and strengthen local manufacturing and distribution capabilities to close access gaps. International partnerships and donor programs continue to play a vital role in many jurisdictions, necessitating alignment between global suppliers and regional program needs. In the Asia-Pacific, manufacturing scale and investment in biologics capability are significant drivers of global supply, while rising domestic demand and government-led manufacturing incentives are accelerating capacity expansion. Across all regions, investment in digital registries and supply chain transparency is improving demand forecasting and immunization coverage measurement, enabling more targeted interventions and better allocation of limited resources.

Strategic company-level perspective revealing how manufacturers are aligning technology investments supply resilience and stakeholder partnerships to sustain pediatric vaccine leadership

Company strategies in the pediatric vaccine space are converging toward three priority themes: technological differentiation, supply chain resilience, and collaborative engagement with public health systems. Leading biological producers are investing to broaden their combination and conjugate portfolios while extending capabilities in recombinant and subunit platforms that facilitate antigen updates and scalable manufacture. Concurrently, players are pursuing capacity enhancements, including modular fill-finish lines and geographically distributed manufacturing nodes, to mitigate disruption risk and to meet country-level sourcing preferences.

Industry participants are also deepening partnerships with contract development and manufacturing organizations, academic centers, and public-private consortia to accelerate development timelines and expand local production. Commercial approaches increasingly bundle product supply with value-added services such as cold chain strengthening, training for health workers, and data sharing agreements that support coverage monitoring. Pricing strategies reflect a balance between ensuring affordability for public programs and preserving margins that sustain ongoing R&D. For smaller or regional manufacturers, focusing on niche disease targets, cost-effective platforms, or specialized distribution agreements offers defensible positions that complement the broader strategies of multinational producers. Overall, corporate success is tied to the ability to integrate scientific innovation with pragmatic manufacturing and stakeholder collaboration.

Actionable recommendations that integrate product innovation supply diversification pricing strategies and stakeholder engagement to drive sustainable pediatric immunization outcomes

Industry leaders should pursue a coordinated set of actions that blend innovation, operational rigor, and stakeholder alignment to improve pediatric vaccine access and program outcomes. First, prioritize development of combination and conjugate formulations that reduce administration complexity and improve adherence, while ensuring that manufacturing investments support flexible production across multiple platforms. Second, invest in diversified sourcing strategies and regional manufacturing options to shield programs from external trade shocks and to meet procurement preferences for local supply assurance.

Third, strengthen end-user engagement by pairing product launches with training, cold chain support, and integration into digital immunization registries to enhance uptake and monitoring. Fourth, adopt tailored pricing and contracting models that balance affordability for public purchasers with incentives for sustained R&D investment, including outcome-based agreements and volume-linked supply commitments. Fifth, deepen collaborations with public health agencies, global donors, and clinical networks to align clinical trial design, post-marketing surveillance, and safety communication strategies. By executing these steps in parallel, companies and health systems can accelerate access to effective pediatric immunizations while building the operational foundations required for long-term program stability.

A transparent research methodology describing primary interviews secondary synthesis and analytical safeguards used to produce validated insights on pediatric vaccine dynamics

The research underpinning this executive summary synthesizes primary stakeholder input with rigorous secondary analysis to ensure balanced and verifiable insights. Primary data were gathered through structured interviews with vaccine developers, manufacturing leaders, procurement specialists, clinical program managers, and policy-makers, which provided real-world perspectives on supply chain constraints, regulatory priorities, and adoption barriers. These qualitative inputs were triangulated with secondary sources including regulatory guidance documents, peer-reviewed literature on vaccine technologies, publicly disclosed corporate filings related to capacity investments, and global immunization program reports to validate observed trends.

Analytical methods included thematic coding of interview data to identify recurring challenges and strategic responses, comparative technology assessment to evaluate platform advantages and constraints, and scenario analysis to explore implications of trade policy and manufacturing shifts. Quality assurance measures involved cross-validation of key findings with domain experts and review of technical assumptions against authoritative clinical and regulatory references. Limitations of the methodology include potential variability in stakeholder perspectives across jurisdictions and the rapidly evolving nature of vaccine science; nonetheless, the combination of primary and secondary inputs offers a robust foundation for the strategic conclusions presented herein.

A concise conclusion synthesizing technological promise operational constraints and strategic priorities that will determine pediatric immunization success

In summary, pediatric vaccines sit at the intersection of accelerating scientific capability and entrenched operational realities. Technological progress in conjugate, recombinant, and combination formulations presents clear pathways to broaden protection while simplifying schedules, yet programmatic adoption hinges on reliable supply, regulatory alignment, and sustained public trust. Trade policy developments and tariff shifts have highlighted the fragility of some global supply linkages and are catalyzing investment in regional capacity, which will reshape procurement relationships and regulatory collaboration in the coming years.

As stakeholders navigate this environment, the most successful strategies will combine targeted product portfolios with resilient manufacturing footprints, thoughtful contracting approaches, and integrated end-user support. Decision-makers who prioritize alignment across R&D, manufacturing, procurement, and program delivery will be best positioned to convert scientific advances into durable public health impact for infants, children, and adolescents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of mRNA technology in pediatric vaccine pipelines for emerging pathogens
  • 5.2. Increased adoption of combination vaccines to reduce injection burden in children
  • 5.3. Growth of digital tracking tools to improve pediatric vaccine adherence and coverage
  • 5.4. Rising focus on vaccine equity initiatives to expand access in underserved pediatric populations
  • 5.5. Development of needle-free delivery methods to enhance vaccine uptake among infants and toddlers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pediatric Vaccines Market, by Vaccine Type

  • 8.1. Hexavalent
  • 8.2. Monovalent
  • 8.3. Pentavalent
  • 8.4. Quadrivalent

9. Pediatric Vaccines Market, by Disease

  • 9.1. DTP
    • 9.1.1. Diphtheria
    • 9.1.2. Pertussis
    • 9.1.3. Tetanus
  • 9.2. Hepatitis B
  • 9.3. Hib
  • 9.4. Measles
  • 9.5. Pneumococcal
  • 9.6. Polio
  • 9.7. Rotavirus

10. Pediatric Vaccines Market, by Technology

  • 10.1. Conjugate
    • 10.1.1. Polysaccharide Conjugate
    • 10.1.2. Protein Conjugate
  • 10.2. Inactivated
    • 10.2.1. Toxoid
    • 10.2.2. Viral
  • 10.3. Live Attenuated
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Recombinant
    • 10.4.1. Mammalian Cell Culture
    • 10.4.2. Yeast Based
  • 10.5. Subunit
    • 10.5.1. Peptide Subunit
    • 10.5.2. Protein Subunit

11. Pediatric Vaccines Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Immunization Centers
  • 11.4. Pharmacies
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies

12. Pediatric Vaccines Market, by Age Group

  • 12.1. Adolescents
  • 12.2. Children
  • 12.3. Infants
  • 12.4. Neonates
  • 12.5. Toddlers

13. Pediatric Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pediatric Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pediatric Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Sanofi S.A.
    • 16.3.5. Serum Institute of India Private Limited
    • 16.3.6. Bharat Biotech International Limited
    • 16.3.7. PT Bio Farma (Persero)
    • 16.3.8. Sinovac Biotech Ltd.
    • 16.3.9. CSL Seqirus Pty Ltd.
    • 16.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PEDIATRIC VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PEDIATRIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEDIATRIC VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025-2032 (USD MILLIO